Results 21 to 30 of about 16,304 (256)

Biosimilars

TURKDERM, 2022
For a drug to be defined as a biosimilar, it should be fairly similar to the previously approved original or reference product. The minor variances in its inactive ingredients should not pose clinically significant differences from the reference product in terms of safety and efficacy potency.
openaire   +3 more sources

An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis

Arthritis Research & Therapy, 2019
Background ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA).
Stanley Cohen, Jose L. Pablos, Karel Pavelka, Gerard Anton Müller, Alan Matsumoto, Alan Kivitz, Hui Wang, Eswar Krishnan   +7 more
doaj   +1 more source

Policies for biosimilar uptake in Europe: An overview. [PDF]

PLoS ONE, 2017
Across European countries, differences exist in biosimilar policies, leading to variations in uptake of biosimilars and divergences in savings all over Europe.The aim of this article is to provide an overview of different initiatives and policies that ...
Evelien Moorkens, Arnold G Vulto, Isabelle Huys, Pieter Dylst, Brian Godman, Simon Keuerleber, Barbara Claus, Maria Dimitrova, Guenka Petrova, Ljiljana Sović-Brkičić, Juraj Slabý, Robin Šebesta, Ott Laius, Allan Karr, Morgane Beck, Jaana E Martikainen, Gisbert W Selke, Susan Spillane, Laura McCullagh, Gianluca Trifirò, Patricia Vella Bonanno, Asbjørn Mack, Antra Fogele, Anita Viksna, Magdalena Władysiuk, Helder Mota-Filipe, Dmitry Meshkov, Marija Kalaba, Simona Mencej Bedrač, Jurij Fürst, Corrine Zara, Peter Skiöld, Einar Magnússon, Steven Simoens   +33 more
doaj   +1 more source

Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria

Pharmaceuticals, 2021
The aim of this study is to evaluate the effect of the introduction of biosimilars in Bulgaria on the prices and utilization of biologic disease modifying antirheumatic drugs (bDMARD).
Konstantin Tachkov, Zornitsa Mitkova, Vladimira Boyadzieva, Guenka Petrova   +3 more
doaj   +1 more source

The structure-function relationship of disulfide bonds in etanercept

Scientific Reports, 2017
Etanercept is a TNFα receptor Fc fusion protein used for the treatment of rheumatic disease and psoriasis. Physicochemical and functional investigation of process fractions during development of the etanercept biosimilar GP2015 (Erelzi®) revealed a ...
William C. Lamanna, Robert Ernst Mayer, Alfred Rupprechter, Michael Fuchs, Fabian Higel, Cornelius Fritsch, Cornelia Vogelsang, Andreas Seidl, Hansjoerg Toll, Martin Schiestl, Johann Holzmann   +10 more
doaj   +1 more source

Pharmacists' confidence in explaining biosimilars to patients before a nationwide medicine change: A cross-sectional study

Exploratory Research in Clinical and Social Pharmacy, 2022
Background: Biosimilars can improve patient access to biological medicines. Although biosimilars have been shown to be equally effective and safe, some patients remain reluctant to transition to biosimilars.
Chiara Gasteiger, Norina Gasteiger, Keith J. Petrie   +2 more
doaj  

Biosimilars in dermatology

Advances in Dermatology and Allergology, 2015
Over the last decade the availability of biological drugs for the treatment of psoriasis vulgaris, psoriatic arthritis and many other inflammatory diseases has revolutionized the treatment of these diseases around the world. Due to the high cost of therapy, the search has started for biosimilars.
Zygmunt Adamski, Małgorzata Mazur, Karolina Olek-Hrab, Jacek Karczewski, Ewa Teresiak-Mikołajczak   +4 more
openaire   +3 more sources

Biosimilar: what it is not [PDF]

British Journal of Clinical Pharmacology, 2015
A biosimilar is a high quality biological medicine shown to be in essence the same as an original product. The European Medicines Agency (EMA) paved the way in the regulatory arena by creating a safeguarding framework for the development of biosimilars.
openaire   +3 more sources

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience? [PDF]

Drugs, 2021
Over time, clinicians have become increasingly comfortable embracing the prescription of biosimilars-highly similar versions of innovator or reference biological agents-for their patients with inflammatory diseases. Although a switch from a reference product to a licensed biosimilar version (or vice versa) is a medical decision robustly supported by ...
Mysler, Eduardo, Azevedo, Valderilio Feijó, Danese, Silvio, Alvarez, Daniel, Iikuni, Noriko, Ingram, Beverly, Mueller, Markus, Peyrin-Biroulet, Laurent   +7 more
openaire   +3 more sources

Evaluation of Physicians’ Knowledge and Attitudes Towards Biosimilars in Russia and Issues Associated with Their Prescribing

Biomolecules, 2019
Physician awareness and perceptions towards biosimilars are important factors in their adoption to clinical practice. Our objectives were to assess levels of knowledge and attitudes towards biosimilars and key policies on their use among Russian ...
Dmitry Karateev, Natalia Belokoneva
doaj   +1 more source